JP2005501031A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501031A5
JP2005501031A5 JP2003510106A JP2003510106A JP2005501031A5 JP 2005501031 A5 JP2005501031 A5 JP 2005501031A5 JP 2003510106 A JP2003510106 A JP 2003510106A JP 2003510106 A JP2003510106 A JP 2003510106A JP 2005501031 A5 JP2005501031 A5 JP 2005501031A5
Authority
JP
Japan
Prior art keywords
agonism
sildenafil
concentration
frequency
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003510106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501031A (ja
Filing date
Publication date
Priority claimed from ES200101535A external-priority patent/ES2180446B1/es
Application filed filed Critical
Publication of JP2005501031A publication Critical patent/JP2005501031A/ja
Publication of JP2005501031A5 publication Critical patent/JP2005501031A5/ja
Pending legal-status Critical Current

Links

JP2003510106A 2001-07-02 2002-07-01 勃起障害の治療における他の薬物の効果を増強するために用いる医薬の生産における2,5−ジヒドロキシベンゼンスルホン酸誘導体の使用 Pending JP2005501031A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200101535A ES2180446B1 (es) 2001-07-02 2001-07-02 Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
PCT/ES2002/000325 WO2003004097A1 (es) 2001-07-02 2002-07-01 Empleo de derivados de ácidos 2,5-dihidroxibencenosulfónicos en la elaboración de un medicamento para potenciar el efecto de otros fármacos en el tratamiento de la disfunción eréctil

Publications (2)

Publication Number Publication Date
JP2005501031A JP2005501031A (ja) 2005-01-13
JP2005501031A5 true JP2005501031A5 (enExample) 2006-01-05

Family

ID=8498259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003510106A Pending JP2005501031A (ja) 2001-07-02 2002-07-01 勃起障害の治療における他の薬物の効果を増強するために用いる医薬の生産における2,5−ジヒドロキシベンゼンスルホン酸誘導体の使用

Country Status (14)

Country Link
US (2) US20040143010A1 (enExample)
EP (1) EP1413332B1 (enExample)
JP (1) JP2005501031A (enExample)
AR (1) AR036124A1 (enExample)
AT (1) ATE419012T1 (enExample)
BR (1) BR0211315A (enExample)
CA (1) CA2453572A1 (enExample)
DE (1) DE60230629D1 (enExample)
ES (2) ES2180446B1 (enExample)
HU (1) HUP0400924A3 (enExample)
MX (1) MXPA04000007A (enExample)
NO (1) NO20040007L (enExample)
PL (1) PL367766A1 (enExample)
WO (1) WO2003004097A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208123A1 (es) * 2002-11-29 2004-06-01 Laboratorios Del Dr. Esteve, S.A. Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
RU2281101C2 (ru) * 2004-10-01 2006-08-10 Юрий Михайлович Есилевский Способ лечения больных хроническим простатитом
EP1676573A1 (en) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
EP2669269B1 (en) 2005-05-27 2019-05-22 The University of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
EP2467173B8 (en) 2009-08-21 2019-06-19 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
CN109678764A (zh) * 2018-12-05 2019-04-26 湖北广辰药业有限公司 一种羟苯双磺酸及其钙盐和制备方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681503A (en) * 1970-04-17 1972-08-01 Om Lab Sa Method for combating disturbances of the lipid content of the blood
US4252821A (en) * 1979-12-07 1981-02-24 Laboratoires Om Societe Anonyme Method for treating ulcers
US4511557A (en) * 1981-08-24 1985-04-16 Gauri Kailash Kumar Pharmaceutical composition
US4513007A (en) * 1983-05-03 1985-04-23 Laboratoires Om Sa Method for treating heart disease
RU1776408C (ru) * 1990-08-13 1992-11-23 Одесский Медицинский Институт Им.Н.И.Пирогова Способ лечени гломерулонефрита
AU715600B2 (en) * 1996-04-03 2000-02-03 Laboratorios Del Dr. Esteve, S.A. Use of 2,5-dihydroxybenzenesulfonic derivatives for the manufacture of medicaments intended for the normalization of the endothelial function, for the treatment of sexual dysfunction and vascular complications of diabetes, as well as vascular disorders of endothelial origin
HU225149B1 (en) * 1996-12-30 2006-07-28 Teva Gyogyszergyar Zrt Use of dobesilate salts for the manufacture of medicaments for the treatment or prevention of embryonic retardation or discordance
US6403643B1 (en) * 1997-04-03 2002-06-11 Laboratories Del Dr. Esteve, S.A. Use of 2,5-dihydroxybenzenesulfonic derivatives for the normalization of endothelial function
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition

Similar Documents

Publication Publication Date Title
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
DE60036968D1 (de) Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen
CN202870468U (zh) 气味型无声闹钟
EP1412371A4 (en) PRODUCTION IN VIVO OF SMALL INTERFERING RNAS THAT MEDIATE GENE SILENCING
WO2004054432A3 (en) Methods and devices for therapeutic treatment cardiac and other pathologies
EP1754804A4 (en) ELECTRODE, OZONE GENERATOR AND OZONE GENERATION PROCESS
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
IL162669A0 (en) Antichlinergic agents, method for producing the same and use thereof as medicaments
DE60314722D1 (de) Zusammensetzung für die pharmazeutische oder dietätische verwendung zur bekämpfung von haarausfall
HUP0501189A3 (en) Drinkable preparation comprising ketoprofen and the use thereof in the simultaneous treatment of a group of animals for processes which are accompanied by fever, inflammation and/or pain
WO2004031202A3 (de) Kondensierte palatinose in hydrierter form
JP2004534810A5 (enExample)
DE60315490D1 (de) Therapeutische behandlung
DE602004014020D1 (de) Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol und 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
EP1591525A3 (de) Oligoribonukleotide zur Behandlung von irritativen und/oder entzündlichen Hauterscheinungen durch RNA-Interferenz
HRP20090513T1 (hr) S-mirtazapin, namijenjen liječenju napadaja vrućine
PT1530462E (pt) Compostos 1-fenil-2-dimetilaminometilciclo-hexano utilizados na terapia dos sintomas depressivos, dor e incontinência
IL165755A0 (en) Avian appesing pheromones to decrease stress, anxiety and aggressiveness
JP2004511523A5 (enExample)
IS7868A (is) Notkun á kortkólíberín-úrókortín kerfi í meðferð á bólguvaldandi sjúkdómum.
ATE416783T1 (de) Verwendung des menschlichen choriongonadotropins in der behandlung von endometriose-symptomen
EP1483407A4 (en) THERAPY AND DIAGNOSTIC PROCEDURES
RU2001130961A (ru) Способ лечения подагры с помощью плазмосорбции
JP2006141695A5 (enExample)
DE60308862D1 (de) Verbindungen und zusammensetzungen zur behandlung von diabetes und erkrankungen, die mit diabetes in zusammenhang stehen